- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Furnish Price to Retailer and Moving Annual Turnover value in respect of 11 Formulations: NPPA
New Delhi: Taking an appropriate action for fixation of the ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India, has released an office memorandum requesting all the manufacturing and marketing companies to furnish the Price to Retailer (PTR) and Moving...
New Delhi: Taking an appropriate action for fixation of the ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, the Government of India, has released an office memorandum requesting all the manufacturing and marketing companies to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of July 2022, in respect of 11 formulations with different dosages.
Table 1
S.No. | Formulation | Brand | Composition & Strength | Dosage/Specification | Price to Retailer (PTR) for July, 2022 | MAT* Sales Value as on July, 2022 (Rs.) | |
Type | Size | ||||||
1. | |||||||
2. | |||||||
3. | |||||||
4. |
S.N. | NLEM, 2022 Section No. | Medicine | Dosage form(s) and strength(s) |
1 | 6.4.2 | Bedaquiline | Tablet100mg |
2 | 7.1.6 | Bendamustinehydrochlorid e | Injection 25 mg/ vial |
3 | 23.5.1 | Buprenorphine | Tablet(Sub-lingual)0.4mg |
4 | 23.5.2 | Buprenorphine (A) +Naloxone (B) | Tablet(Sub-lingual)0.4mg(A)+0.1mg(B) |
5 | 23.5.2 | Buprenorphine (A) +Naloxone (B) | Tablet(Sub-lingual)2mg(A)+0.5mg(B) |
6 | 6.8.1 | Daclatasvir | Tablet30mg |
7 | 6.4.6 | Delamanid | Tablet50mg |
8 | 7.1.26 | Irinotecan HCltrihydrate | Solutionforinjection20mg/mL |
9 | 6.2.2.11 | Phenoxymethyl penicillin | Tablet250mg |
10 | 6.2.2.12 | ProcaineBenzylpenicillin | Powder for injection1000mg(=1millionIU) |
11 | 6.7.1.6 | TenofovirDisproxilFumarate (A) +Lamivudine(B)+Dolutegra vir(c) | Tablet300mg(A)+300mg(B)+50 mg(c) |
12 | 6.6.2.1 | Valganciclovir* | Powder for oral solution 50mg / mL |
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.